Skip to main navigation Skip to search Skip to main content

The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy

  • Ping Tao Tseng
  • , Chun Pai Yang
  • , Kuan Pin Su
  • , Tien Yu Chen
  • , Yi Cheng Wu
  • , Yu Kang Tu
  • , Pao Yen Lin
  • , Brendon Stubbs
  • , Andre F. Carvalho
  • , Yutaka J. Matsuoka
  • , Dian Jeng Li
  • , Chih Sung Liang
  • , Chih Wei Hsu
  • , Yen Wen Chen
  • , Yow Ling Shiue*
  • *Corresponding author for this work
  • WinShine Clinics in Specialty of Psychiatry
  • Prospect Clinic for Otorhinolaryngology & Neurology
  • National Sun Yat-sen University
  • Kuang Tien General Hospital
  • Hungkuang University
  • China Medical University Taichung
  • Triservice General Hospital Taiwan
  • National Yang Ming Chiao Tung University
  • Landseed International Hospital
  • National Taiwan University
  • Chang Gung University
  • Chang Gung Memorial Hospital
  • King's College London
  • South London and Maudsley NHS Foundation Trust
  • Anglia Ruskin University
  • University of Toronto
  • National Cancer Center Japan
  • Kaohsiung Municipal Kai-Syuan Psychiatric Hospital
  • National Defense Medical University

Research output: Contribution to journal › Journal Article › peer-review

37 Scopus citations

Abstract

Although exogenous melatonin supplementation has been suggested to be effective for episodic migraine prophylaxis, there is no conclusive evidence comparing the efficacy of exogenous melatonin supplementation to the other FDA-approved pharmacotherapy for episodic migraine prophylaxis. The aim of the current network meta-analysis (NMA) was to compare the efficacy of exogenous melatonin supplementation in patients with episodic migraine. The randomized placebo-controlled trials or randomized controlled trials (RCTs) incorporating a placebo in the study designs were included in our analyses. All of the NMA procedures were conducted under the frequentist model. The primary outcome was changes in frequency of migraine days and response rate after migraine prophylaxis with melatonin supplementation or pharmacological interventions. We included 25 RCTs in total with 4499 patients (mean age = 36.0 years, mean female proportion = 78.9%). The NMA demonstrated that migraine prophylaxis with oral melatonin 3 mg/d (immediate-release) at bedtime was associated with the greatest improvement in migraine frequency [mean difference = −1.71 days, 95% confidence interval (CI): −3.27 to −0.14 days compared to placebo] and the second highest response rate (odds ratio = 4.19, 95% CI = 1.46 to 12.00 compared to placebo). Furthermore, oral melatonin 3 mg (immediate-release) at bedtime was the most preferred pharmacological intervention among all of the investigated interventions when improvements in migraine frequency, response rate, dropout rate, and rates of any adverse events were taken into account. This pilot NMA suggests the potential prophylactic role of exogenous melatonin supplementation in patients with episodic migraine.

Original languageEnglish
Article numbere12663
JournalJournal of Pineal Research
Volume69
Issue number2
DOIs
StatePublished - 01 09 2020

Bibliographical note

Publisher Copyright:
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Keywords

  • circadian rhythm
  • melatonin
  • migraine
  • network meta-analysis
  • sleep

Fingerprint

Dive into the research topics of 'The association between melatonin and episodic migraine: A pilot network meta-analysis of randomized controlled trials to compare the prophylactic effects with exogenous melatonin supplementation and pharmacotherapy'. Together they form a unique fingerprint.

Cite this